Comparative Pharmacology
Head-to-head clinical analysis: JENTADUETO XR versus SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JENTADUETO XR versus SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE.
JENTADUETO XR vs SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JENTADUETO XR combines linagliptin, a DPP-4 inhibitor that increases incretin levels (GLP-1, GIP) leading to glucose-dependent insulin secretion and decreased glucagon release, and metformin, an AMPK activator that decreases hepatic gluconeogenesis, reduces intestinal glucose absorption, and improves insulin sensitivity.
Saxagliptin inhibits dipeptidyl peptidase-4 (DPP-4), increasing incretin levels (GLP-1, GIP), enhancing glucose-dependent insulin secretion, and suppressing glucagon release. Metformin reduces hepatic gluconeogenesis, decreases intestinal glucose absorption, and improves insulin sensitivity.
The usual starting dose of JENTADUETO XR (empagliflozin/metformin extended-release) is 5 mg/1000 mg orally once daily with the evening meal. Dose can be increased to a maximum of 12.5 mg/2000 mg once daily based on glycemic control and tolerability.
Initial dose: 2.5 mg saxagliptin/500 mg metformin hydrochloride orally twice daily with meals. Titrate up to max 5 mg/1000 mg twice daily.
None Documented
None Documented
Linagliptin: 12 h (terminal, steady-state) with once-daily dosing providing sustained DPP-4 inhibition. Metformin: 6.2 h (terminal elimination) in patients with normal renal function; prolonged in renal impairment, contraindicated if eGFR < 30 mL/min/1.73 m².
Saxagliptin: 2.5 hours; 5-hydroxy saxagliptin (active metabolite): 3.1 hours. Metformin: 4.5-6.2 hours. Total combined half-life 2-6 hours, requiring twice-daily dosing.
Linagliptin: ~90% excreted unchanged in feces via enterohepatic recycling, <5% renally eliminated. Metformin: ~90% eliminated unchanged in urine via glomerular filtration and tubular secretion, <10% in feces.
Saxagliptin: 75% renal (50% unchanged, 25% as metabolite), 22% fecal. Metformin: 90-100% renal unchanged via tubular secretion.
Category C
Category A/B
DPP-4 Inhibitor / Biguanide Combination
DPP-4 Inhibitor